| Company* (Country; Symbol) | Company (Country; Symbol) | Type/Product Area | Terms/Details (Date) |
| I. MODIFIED AGREEMENTS | |||
| Alnylam Pharmaceuticals Inc. (ALNY) | Medtronic Inc. (NYSE:MDT) | Expanded deal to develop drug-device combination products utilizing RNAi to treat central nervous system diseases | The original deal called for Alnylam to handle discovery and early development work while Medtronic would manage late-stage trials and commercialization; Medtronic would pay milestones and royalties; now, the deal is a 50/50 co-development and profit sharing arrangement in the U.S.; Alnylam has the opportunity to invest in clinical development; in Europe, Medtronic will handle development and commercialization and will pay Alnylam royalties (7/30) |
| Archemix Corp.* | SomaLogic Inc.* | Expanded alliance focused on the use and development of aptamers for therapeutic, diagnostic and other applications | Archemix received exclusive rights to therapeutic uses of aptamers discovered by SomaLogic for a limited number of targets; SomaLogic will receive rights to all ex vivo uses of aptamers it did not previously hold, including the use of aptamers for affinity purification (8/8) |
|
Exact Sciences Corp. (EXAS) |
Laboratory Corp. of America Holdings (NYSE:LH) | Expanded licensing agreement for broader distribution of Exact's DNA technology for colorectal cancer screening | Exact agreed to extend LabCorp's exclusivity period through 2010 in exchange for other terms (6/28) |
| Silence Therapeutics plc* (UK) | Quark Pharmaceuticals Inc.* | Expanded technology license agreement to provide Quark with options to nonexclusive licenses to develop additional molecules against three specific targets using Silence's AtuRNAi technology | The original deal, signed in April 2005, provided Quark with access to the technology to develop RTP801i; under the expanded agreement, Silence is entitled to milestone payments and a royalty on product sales (7/31) |
| Tercica Inc. (TRCA) | Genentech Inc.(NYSE:DNA) | Expanded collaboration to develop combination IGF-1 and growth hormone products for idiopathic short stature and adult growth hormone deficiency | The deal could be worth up to $53M to Tercica, including $13M in equity investments, as well as opt-in payments, reimbursements and milestone payments (7/11) |
| II. TERMINATED AGREEMENTS | |||
| Anadys Pharmaceuticals Inc. (ANDS) | LG Life Sciences* (South Korea) | Temrinated agreement for the hepatitis B drug ANA360 | The company terminated the program in order to refocus resources on ANA598, an antiviral for hepatitis C, and ANA773, a TLR7 agonist prodrug for cancer (8/2) |
| The Medicines Co. (MDCO) | Nycomed A/S* (Denmark) | The Medicines Co. reacquired all European development and commercial rights to Angiox (bivalirudin) | The company plans to sell the product itself in Europe; Nycomed gets $20M up front and $20M next year, and would get another $5M if European regulators approve an expanded Angiox label (7/2) |
| Viragen Inc. (AMEX:VRA) | Oxford Biomedica plc (UK; LSE:OXB) | Viragen halted development of its OVA avian transgenic protein manufacturing technology leading to the termination of its agreements with Oxford Biomedica and the Roslin Institute | Viragen decided to stop development because of the large gap between research and commercialization (6/22) |
| Notes: | |||
| * Private companies are indicated with an asterisk. | |||
| Unless otherwise noted, stock symbols listed are on the Nasdaq market. | |||
| AMEX = American Stock Exchange; LSE = London Stock Exchange; NYSE = New York Stock Exchange. | |||
